Abstract
Nano-engineered particles have been developed to reach specific molecular targets on diseased cells and have been used in various experimental and clinical conditions. The medical application involves diagnostic and therapeutic applications and a large deal of this research concerns malignant disease. Various approaches have been tried to effectively reach the cancer cell and PEGylated liposomes have demonstrated targeting and controlled release of antineoplastic drugs. For cancer diagnostics nanoparticles have been engineered to optimize magnetic resonance imaging, ultrasound imaging and nuclear medicine imaging. Radiolabeled nanoparticles can also be used for therapeutic purposes when tagged with appropriate radionuclides. This article aims to provide an overview how nanomedicine is presently influencing drug design and, more specifically, the development of radiopharmaceuticals for cancer management.
Keywords: Nanoparticles, nanocarriers, oncology, therapy, imaging
Current Radiopharmaceuticals
Title: Nanoparticles in Cancer
Volume: 1 Issue: 1
Author(s): Ernest K.J. Pauwels, Kalevi Kairemo, Paola Erba and Kim Bergstrom
Affiliation:
Keywords: Nanoparticles, nanocarriers, oncology, therapy, imaging
Abstract: Nano-engineered particles have been developed to reach specific molecular targets on diseased cells and have been used in various experimental and clinical conditions. The medical application involves diagnostic and therapeutic applications and a large deal of this research concerns malignant disease. Various approaches have been tried to effectively reach the cancer cell and PEGylated liposomes have demonstrated targeting and controlled release of antineoplastic drugs. For cancer diagnostics nanoparticles have been engineered to optimize magnetic resonance imaging, ultrasound imaging and nuclear medicine imaging. Radiolabeled nanoparticles can also be used for therapeutic purposes when tagged with appropriate radionuclides. This article aims to provide an overview how nanomedicine is presently influencing drug design and, more specifically, the development of radiopharmaceuticals for cancer management.
Export Options
About this article
Cite this article as:
Pauwels K.J. Ernest, Kairemo Kalevi, Erba Paola and Bergstrom Kim, Nanoparticles in Cancer, Current Radiopharmaceuticals 2008; 1 (1) . https://dx.doi.org/10.2174/1874471010801010030
DOI https://dx.doi.org/10.2174/1874471010801010030 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Graphene and Graphene Oxide as a Docking Station for Modern Drug Delivery System
Current Drug Delivery Light Chain LC and TAT-EGFP-HCS of Botulinum Toxin Expression and Biological Function <i>in vitro</i> and <i>in vivo</i>
Current Proteomics Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued) Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design Brain Tumor Segmentation Using Deep Belief Networks and Pathological Knowledge
CNS & Neurological Disorders - Drug Targets Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry MicroRNA Dysregulation in Gastric Cancer
Current Pharmaceutical Design Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation
Current Pharmaceutical Design BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets Advanced Micro-Nano-Bio Systems for Future Targeted Therapies
Current Nanoscience Friend or Foe: UCHL3 Mediated Carcinogenesis and Current Approaches in Small Molecule Inhibitors’ Development
Current Medicinal Chemistry Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Nanoparticulate Formulations for Paclitaxel Delivery Across MDCK Cell Monolayer
Current Pharmaceutical Design